image
Pacific Biosciences of California, Inc. PACB
Healthcare - Medical - Devices - NASDAQ - US
Watchlist
$ 1.27
-3.05 %
$ 381 M
Market Cap
-0.46
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jun, 21, 2025.

The intrinsic value of one PACB stock under the worst case scenario is HIDDEN Compared to the current market price of 1.27 USD, Pacific Biosciences of California, Inc. is HIDDEN

PACB Intrinsic Value
HIDDEN
SHOW

This DCF valuation model was last updated on Jun, 21, 2025.

The intrinsic value of one PACB stock under the base case scenario is HIDDEN Compared to the current market price of 1.27 USD, Pacific Biosciences of California, Inc. is HIDDEN

PACB Intrinsic Value
HIDDEN
SHOW

This DCF valuation model was last updated on Jun, 21, 2025.

The intrinsic value of one PACB stock under the best case scenario is HIDDEN Compared to the current market price of 1.27 USD, Pacific Biosciences of California, Inc. is HIDDEN

PACB Intrinsic Value
HIDDEN
SHOW
2. FUNDAMENTAL ANALYSIS

Price Chart PACB

image
1M 23%
6M -44%
1Y -3%
3Y -306%
5Y -209%
All
$2.2$2.2$2.0$2.0$1.8$1.8$1.6$1.6$1.4$1.4$1.2$1.2$1.0$1.0$0.8$0.8Jan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '2515 Jun15 Jun
FINANCIALS
154 M REVENUE
-23.19%
Growth Rates
1Year -23.19%
3Years 5.67%
5Years 11.12%
7Years 7.40%
10Years 9.78%
-356 M OPERATING INCOME
-6.55%
Growth Rates
1Year -6.55%
3Years -26.00%
5Years -28.80%
7Years -21.77%
10Years -18.95%
-310 M NET INCOME
-1.02%
Growth Rates
1Year -1.02%
3Years -19.58%
5Years -29.79%
7Years -18.91%
10Years -16.70%
-206 M OPERATING CASH FLOW
20.49%
Growth Rates
1Year 20.49%
3Years -22.83%
5Years -21.35%
7Years -17.28%
10Years -14.88%
124 M INVESTING CASH FLOW
2593.40%
Growth Rates
1Year 2593.40%
3Years 29.72%
5Years 14.85%
7Years 87.69%
10Years 20.28%
-43 M FINANCING CASH FLOW
-39.48%
Growth Rates
1Year -39.48%
3Years -1.21%
5Years -21.24%
7Years -7.18%
10Years -7.30%
37.2 M REVENUE
-5.28%
Growth Rates
1Year -23.19%
3Years 5.67%
5Years 11.12%
7Years 7.40%
10Years 9.78%
-403 M OPERATING INCOME
-163.09%
Growth Rates
1Year -6.55%
3Years -26.00%
5Years -28.80%
7Years -21.77%
10Years -18.95%
-426 M NET INCOME
-17970.27%
Growth Rates
1Year -1.02%
3Years -19.58%
5Years -29.79%
7Years -18.91%
10Years -16.70%
-44.1 M OPERATING CASH FLOW
-43.74%
Growth Rates
1Year 20.49%
3Years -22.83%
5Years -21.35%
7Years -17.28%
10Years -14.88%
45.2 M INVESTING CASH FLOW
-22.33%
Growth Rates
1Year 2593.40%
3Years 29.72%
5Years 14.85%
7Years 87.69%
10Years 20.28%
1.96 M FINANCING CASH FLOW
103.90%
Growth Rates
1Year -39.48%
3Years -1.21%
5Years -21.24%
7Years -7.18%
10Years -7.30%
Balance Sheet Pacific Biosciences of California, Inc.
image
Current Assets 496 M
Cash & Short-Term Investments 390 M
Receivables 27.5 M
Other Current Assets 78.2 M
Non-Current Assets 765 M
Long-Term Investments 0
PP&E 46.6 M
Other Non-Current Assets 718 M
30.94 %6.21 %3.70 %56.98 %Total Assets$1.3b
Current Liabilities 66.3 M
Accounts Payable 16.6 M
Short-Term Debt 10 M
Other Current Liabilities 39.7 M
Non-Current Liabilities 688 M
Long-Term Debt 662 M
Other Non-Current Liabilities 25.1 M
5.26 %87.87 %3.34 %Total Liabilities$753.9m
EFFICIENCY
Earnings Waterfall Pacific Biosciences of California, Inc.
image
Revenue 154 M
Cost Of Revenue 117 M
Gross Profit 37.3 M
Operating Expenses 394 M
Operating Income -356 M
Other Expenses -46.5 M
Net Income -310 M
200m200m100m100m00(100m)(100m)(200m)(200m)(300m)(300m)(400m)(400m)154m(117m)37m(394m)(356m)47m(310m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
24.21% GROSS MARGIN
24.21%
Averages
1Year 24.21%
3Years 29.58%
5Years 35.02%
7Years 35.01%
10Years 38.85%
-231.40% OPERATING MARGIN
-231.40%
Averages
1Year -231.40%
3Years -212.54%
5Years -181.29%
7Years -163.64%
10Years -135.15%
-201.18% NET MARGIN
-201.18%
Averages
1Year -201.18%
3Years -199.69%
5Years -140.13%
7Years -130.96%
10Years -113.15%
-61.16% ROE
-61.16%
Averages
1Year -61.16%
3Years -53.58%
5Years -34.97%
7Years -58.07%
10Years -64.45%
-24.58% ROA
-24.58%
Averages
1Year -24.58%
3Years -19.98%
5Years -12.37%
7Years -24.95%
10Years -31.68%
-29.63% ROIC
-29.63%
Averages
1Year -29.63%
3Years -22.73%
5Years -20.35%
7Years -33.11%
10Years -39.94%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Pacific Biosciences of California, Inc.
image
50m50m00(50m)(50m)(100m)(100m)(150m)(150m)(200m)(200m)(250m)(250m)(300m)(300m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -310 M
Depreciation & Amortization 53.3 M
Capital Expenditures -6.19 M
Stock-Based Compensation 71 M
Change in Working Capital -40.6 M
Others 20.2 M
Free Cash Flow -212 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Pacific Biosciences of California, Inc.
image
Wall Street analysts predict an average 1-year price target for PACB of $2.9 , with forecasts ranging from a low of $2 to a high of $4 .
PACB Lowest Price Target Wall Street Target
2 USD 57.48%
PACB Average Price Target Wall Street Target
2.9 USD 128.35%
PACB Highest Price Target Wall Street Target
4 USD 214.96%
Price
Max Price Target
Min Price Target
Average Price Target
4444333322221111Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26Jun '26Jun '26Jul '26Jul '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 4
6. Ownership
Insider Ownership Pacific Biosciences of California, Inc.
image
Sold
0-3 MONTHS
5.2 K USD 1
3-6 MONTHS
824 K USD 3
6-9 MONTHS
34.1 K USD 1
9-12 MONTHS
278 K USD 3
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Pacific Biosciences of California (PACB) Outperforms Broader Market: What You Need to Know Pacific Biosciences of California (PACB) closed at $1.18 in the latest trading session, marking a +1.72% move from the prior day. zacks.com - 3 weeks ago
Here's Why You Should Add PacBio Stock to Your Portfolio Now PACB benefits from strong first-quarter results, product innovation, and cost cuts to offset sales cycle delays and drive 2025 growth. zacks.com - 4 weeks ago
Target ALS Chooses PacBio HiFi Sequencing to Advance ALS Research with Largest Global Genomic Study to Date Organization's 6,000-genome effort will power global ALS research through detailed long-read sequencing data made freely available to scientists worldwide NEW YORK and MENLO PARK, Calif. , June 2, 2025 /PRNewswire/ -- Target ALS, a nonprofit breaking down barriers to amyotrophic lateral sclerosis (ALS) research, has partnered with PacBio (Nasdaq: PACB), a leading provider of high-quality, highly accurate long read sequencing platforms, to launch the largest global whole genome sequencing initiative for ALS to date. prnewswire.com - 1 month ago
All You Need to Know About Pacific Biosciences (PACB) Rating Upgrade to Buy Pacific Biosciences (PACB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). zacks.com - 1 month ago
PacBio Stock Slips Despite New China Distribution Deal With Haorui PACB expands reach in China through Haorui Gene partnership, bringing HiFi sequencing to new clinical labs and boosting precision medicine access nationwide. zacks.com - 1 month ago
PACB Stock May Rise Following the Deal With Chulalongkorn University PacBio and Chulalongkorn University launch Asia Pacific's first population-scale HiFi WGS newborn screening program, advancing precision medicine in Thailand. zacks.com - 1 month ago
PacBio Board Independent Investigation Concludes Allegations Unsubstantiated MENLO PARK, Calif., May 12, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced that the Special Committee of its Board of Directors (the “Special Committee”) has concluded its independent investigation into previously disclosed allegations from an attorney representing an employee impacted by our recent reduction in force regarding certain employment practices and cybersecurity matters of the Company. The allegations did not involve the current, or any previously reported, financial results, and the investigation found no improper employment practices and no material inaccuracies or omissions with respect to the cybersecurity disclosures in the Company's 2024 Form 10-K. globenewswire.com - 1 month ago
PacBio Stock Down Despite Q1 Earnings & Revenue Beat Estimates Despite strong Service and other revenues, PACB reports soft first-quarter 2025 results partly due to lower Revio system shipments. zacks.com - 1 month ago
Pacific Biosciences (PACB) Reports Q1 Earnings: What Key Metrics Have to Say While the top- and bottom-line numbers for Pacific Biosciences (PACB) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values. zacks.com - 1 month ago
Pacific Biosciences of California, Inc. (PACB) Q1 2025 Earnings Call Transcript Pacific Biosciences of California, Inc. (NASDAQ:PACB ) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants Todd Friedman - Senior Director, Finance & Investor Relations Christian Henry - President & Chief Executive Officer Jim Gibson - Chief Financial Officer Conference Call Participants Jack Meehan - Nephron Research David Westenberg - Piper Sandler William Ruby - TD Cowen Operator Good afternoon, everyone. And welcome to the PacBio First Quarter 2025 Earnings Conference Call. seekingalpha.com - 1 month ago
Pacific Biosciences of California (PACB) Reports Q1 Loss, Tops Revenue Estimates Pacific Biosciences of California (PACB) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to loss of $0.26 per share a year ago. zacks.com - 1 month ago
PacBio Announces First Quarter 2025 Financial Results MENLO PARK, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter ended March 31, 2025. globenewswire.com - 1 month ago
8. Profile Summary

Pacific Biosciences of California, Inc. PACB

image
COUNTRY US
INDUSTRY Medical - Devices
MARKET CAP $ 381 M
Dividend Yield 0.00%
Description Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company provides PacBio's Systems, which conduct, monitor, and analyse biochemical sequencing reactions; consumable products, including single molecule real-time (SMRT) cells; and various reagent kits designed for specific workflow, such as template preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. The company serves research institutions; commercial laboratories; genome centers; public health labs, hospitals and clinical research institutes, contract research organizations, and academic institutions; pharmaceutical companies; and agricultural companies. It markets its products through a direct sales force in North America and Europe, as well as through distribution partners in Asia, Europe, the Middle East, Africa, and Latin America. Pacific Biosciences of California, Inc. has a development and commercialization agreement with Invitae Corporation. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.
Contact 1305 O’Brien Drive, Menlo Park, CA, 94025 https://www.pacb.com
IPO Date Oct. 27, 2010
Employees 575
Officers Ms. Michele Farmer CPA Vice President & Chief Accounting Officer Ms. Natalie Welch Chief People Officer Mr. James R. Gibson II Chief Financial Officer Mr. David Ruggiero Global Head of Sales & Service Mr. Christian O. Henry M.B.A. President, Chief Executive Officer & Director Dr. Stephen Turner Ph.D. Co-Founder Dr. Brett Atkins J.D., Ph.D. General Counsel & Corporate Secretary Mr. Mark Van Oene Ph.D. Chief Operating Officer